0
Editorials: Point and Counterpoint |

POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Christopher S. King, MD, FCCP; Steven D. Nathan, MD, FCCP
Author and Funding Information

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: S. D. N. is on speaker’s bureaus and advisory boards and has received financial support for research from Roche and Boerhinger Ingelheim. None declared (C. S. K.).

Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA

CORRESPONDENCE TO: Christopher S. King, MD, FCCP, Inova Fairfax Hospital, Advanced Lung Disease and Transplantation Clinic, 3300 Gallows Rd, Falls Church, VA 22042


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(2):273-275. doi:10.1016/j.chest.2016.04.034
Text Size: A A A
Published online

Extract

The lack of medical options for the treatment of idiopathic pulmonary fibrosis (IPF) has long been a source of frustration and consternation for pulmonologists treating this deadly disorder. This previously led to the adoption of therapies with little supportive data, some of which have subsequently proved not only to be ineffective but also deleterious., The early 2000s heralded a new era in clinical trials for IPF, with multiple multicenter studies being successfully completed. A wealth of valuable information about the natural history of the disease, but few positive studies, emanated from these robust clinical trials. These studies also spawned a certain amount of controversy regarding suitable and acceptable end points for IPF clinical trials. The labor and commitment of many patients, physicians, principal investigators, research coordinators, pharmaceutical companies, and governmental agencies finally bore fruit with two drugs being approved for the treatment of IPF contemporaneously by the US Food and Drug Administration (FDA). This has marked a turning point and a new era in the management of these patients. Although the development of efficacious pharmacologic therapy for IPF has provided renewed hope for this deadly disease, it has also led to many questions regarding the optimal use of these agents. Who should be prescribed these medications, when should they be started, and when, if ever, should they be stopped?

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543